Physician profile
Denise Wade
NPI 1376871970
$2,574.39
in general payments reported to CMS, 2019-2025
11 companies · $88.43 in 2025
The $88.43 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $214 · 2023: $100 · 2024: $2,171 · 2025: $88.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,296 · Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,296.26 |
| Food and Beverage | $1,064.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,503.23 | 2024 | |
| Amneal Pharmaceuticals LLC | $238.16 | 2024-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Alexion Pharmaceuticals, INC. | $236.08 | 2024 | Ultomiris |
| Vertos Medical, INC. | $193.44 | 2024 | Mild Device Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $112.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $76.74 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $68.17 | 2022 | |
| Abbvie INC. | $65.53 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $33.42 | 2024 | Ingrezza |
| Collegium Pharmaceutical, INC. | $33.08 | 2022 | |
| Kyowa Kirin, INC. | $13.73 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.